AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-κB pathways

Atherosclerosis

Volumn 208, Issue 1, 2010, Pages 34-42

  Liu, YaYang ^a   Liang, Chun ^a   Liu, Xing ^a   Liao, Bin ^a   Pan, Xiaoming ^a   Ren, Yusheng ^a   Fan, Min ^a   Li, Mei ^a   He, Zhiqing ^a   Wu, Jianxiang ^a   Wu, ZongGui ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Adventitial fibroblasts; Angiotensin receptor blocker; Cell movement; Inflammatory response; Mitogen activated protein kinase; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CANDESARTAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ARTICLE; BLOOD VESSEL WALL; CELL ISOLATION; CELL MIGRATION; CELL SYNCHRONIZATION; DIABETES MELLITUS; DRUG MECHANISM; FIBROBLAST; FIBROBLAST CULTURE; GENETIC TRANSCRIPTION; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SPRAGUE DAWLEY RAT; UPREGULATION;

ANIMALS; CELL MOVEMENT; CELLS, CULTURED; FIBROBLASTS; GLYCOSYLATION END PRODUCTS, ADVANCED; INFLAMMATION; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 73449133329     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.06.007     Document Type: Article

References (37)

1. Xu F., Ji J., Li L., Chen R., and Hu W. Activation of adventitial fibroblasts contributes to the early development of atherosclerosis: a novel hypothesis that complements the "Response-to-Injury Hypothesis" and the "Inflammation Hypothesis". Med Hypotheses 69 (2007) 908-912
2. Sartore S., Chiavegato A., Faggin E., et al. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. Circ Res 89 (2001) 1111-1121
3. Siow R.C., Mallawaarachchi C.M., and Weissberg P.L. Migration of adventitial myofibroblasts following vascular balloon injury: insights from in vivo gene transfer to rat carotid arteries. Cardiovasc Res 59 (2003) 212-221
4. Xu F., Ji J., Li L., Chen R., and Hu W.C. Adventitial fibroblasts are activated in the early stages of atherosclerosis in the apolipoprotein E knockout mouse. Biochem Biophys Res Commun 352 (2007) 681-688
5. Haurani M.J., and Pagano P.J. Adventitial fibroblast reactive oxygen species as autacrine and paracrine mediators of remodeling: bellwether for vascular disease?. Cardiovasc Res 75 (2007) 679-689
6. Li G., Chen S.J., Oparil S., Chen Y.F., and Thompson J.A. Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries. Circulation 101 (2000) 1362-1365
7. Okamoto E., Couse T., De Leon H., et al. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation 104 (2001) 2228-2235
8. Rayner K., Van Eersel S., Groot P.H., and Reape T.J. Localisation of mRNA for JE/MCP-1 and its receptor CCR2 in atherosclerotic lesions of the ApoE knockout mouse. J Vasc Res 37 (2000) 93-102
9. Zalewski A., and Shi Y. Vascular myofibroblasts. Lessons from coronary repair and remodeling. Arterioscler Thromb Vasc Biol 17 (1997) 417-422
10. Jandeleit-Dahm K., and Cooper M.E. The role of AGEs in cardiovascular disease. Curr Pharm Des 14 (2008) 979-986
11. Yamagishi S., Matsui T., and Nakamura K. Blockade of the advanced glycation end products (AGEs) and their receptor (RAGE) system is a possible mechanism for sustained beneficial effects of multifactorial intervention on mortality in type 2 diabetes. Med Hypotheses 71 (2008) 749-751
12. Yamagishi S., Nakamura K., Matsui T., et al. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs 17 (2008) 983-996
13. Yamagishi S., and Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11 (2005) 2279-2299
14. Yoshida T., Yamagishi S., Nakamura K., et al. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation. Diabetologia 49 (2006) 3094-3099
15. Yoshiko Ihara K.E., Nakano K., Ohtani K., et al. Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis. J Mol Cell Cardiol 43 (2007) 455-464
16. Candido R., Allen T.J., Lassila M., et al. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 109 (2004) 1536-1542
17. Candido R., Jandeleit-Dahm K.A., Cao Z., et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 106 (2002) 246-253
18. 2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species. Atherosclerosis 195 (2007) 39-47
19. Johnstone M.T., Perez A.S., Nasser I., et al. Angiotensin receptor blockade with candesartan attenuates atherosclerosis, plaque disruption, and macrophage accumulation within the plaque in a rabbit model. Circulation 110 (2004) 2060-2065
20. Li G., Chen Y.F., Greene G.L., Oparil S., and Thompson J.A. Estrogen inhibits vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation 100 (1999) 1639-1645
21. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
22. Sakata N., Meng J., and Takebayashi S. Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J Atheroscler Thromb 7 (2000) 169-176
23. Goldin A., Beckman J.A., Schmidt A.M., and Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114 (2006) 597-605
24. Shi Y., O'Brien J.E., Fard A., et al. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 94 (1996) 1655-1664
25. Diez-Juan A., and Andres V. Coordinate control of proliferation and migration by the p27Kipl/cyclin cyclindependent kinase retinoblastoma pathway in vascular smooth muscle cells and fibroblasts. Circ Res 92 (2003) 402-410
26. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 196 (2008) 9-21
27. Zhong Y., Li S.H., Liu S.M., et al. C-reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Hypertension 48 (2006) 504-511
28. Nakamura K., Yamagishi S., Adachi H., et al. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev 24 (2008) 109-114
29. Isik F.F., Coughlin S.R., Nelken N.A., Clowes A.W., and Gordon D. JE gene expression in an animal model of acute arterial graft rejection. J Surg Res 60 (1996) 224-231
30. Harja E., Bu D.X., Hudson B.I., et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest 118 (2008) 183-194
31. Basta G., Lazzerini G., Massaro M., et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105 (2002) 816-822
32. Bierhaus A., Schiekofer S., Schwaninger M., et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50 (2001) 2792-2808
33. Ghosh S., and Karin M. Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl. (2002) S81-96
34. Li Q., and Verma I.M. NF-kappaB regulation in the immune system. Nat Rev Immunol 2 (2002) 725-734
35. Zerfaoui M., Suzuki Y., Naura A.S., et al. Nuclear translocation of p65 NF-κB is sufficient for VCAM-1, but not ICAM-1, expression in TNF-stimulated smooth muscle cells: differential requirement for PARP-1 expression and interaction?. Cell Signal 20 (2008) 186-194
36. Wautier M.P., Chappey O., Corda S., et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280 (2001) E685-694
37. Wilson S.H., Caplice N.M., Simari R.D., et al. Activated nuclear factor-kappaB is present in the coronary vasculature in experimental hypercholesterolemia. Atherosclerosis 148 (2000) 23-30